MARKSANS
Marksans Pharma
Each stock's 10,000-path forecast, rendered as light.
Marksans Pharma (MARKSANS) Stock Analysis & Case Study
Is MARKSANS a good buy? The data-driven verdict.
Marksans Pharma (MARKSANS) trades at ₹256,on the numbers it mixed signals, a Downstox Snapshot Score of 54/100.
On the numbers, Marksans Pharma (MARKSANS) mixed signals, a Downstox Snapshot Score of 54/100, weighing premium at 27.7× earnings, ROE of 15.2%, a 60% model probability of trading higher in a year. Below: the full bull case, bear case, sector-relative valuation, and a probability-weighted price target for 2027–2031.
Last updated . Data snapshot for research, not investment advice.
MARKSANS fundamentals at a glance, PE, PB, ROE, ROCE, market cap, dividend yield
Is MARKSANS overvalued? MARKSANS P/E vs its sector
MARKSANS's P/E of 27.7× sits above the sector peer median of 15.9×, so on earnings it screens richer than peers, while its 0.31% dividend yield is below the peer median of 1.65%.
MARKSANS share price target 2027, 2028, 2029, 2030, 2031, a probability view
Unlike a single guessed number, this is a probability-weighted range from a 10,000-path Monte-Carlo simulation on 2.0y of MARKSANS history (23%/yr drift, 47%/yr volatility).
| Year | Low (P10) | Median target (P50) | High (P90) | Upside vs today |
|---|---|---|---|---|
| MARKSANS 2027 | ₹158 | ₹293 | ₹537 | +13% |
| MARKSANS 2028 | ₹142 | ₹328 | ₹763 | +26% |
| MARKSANS 2029 | ₹129 | ₹372 | ₹1,056 | +43% |
| MARKSANS 2030 | ₹121 | ₹418 | ₹1,403 | +61% |
| MARKSANS 2031 | ₹122 | ₹472 | ₹1,841 | +82% |
Median (P50) is the central estimate; the P10–P90 band is the 80% confidence range. Probabilities, not promises.
What is the probability MARKSANS goes up, or doubles?
The bull case for MARKSANS
- A healthy 15.2% return on equity.
- Strong ROCE (18.8%) shows the core business earns well above its cost of capital.
- A 10,000-path probability model puts a 60% chance the price is higher in a year, with a median target of ₹293 (+13%).
- Upside scenario: the model's optimistic (P90) 3-year path reaches ₹1,056.
The bear case & risks
- At 27.7× earnings the stock carries a premium to the market, strong growth is already in the price, so any miss tends to be punished.
- High historical volatility (47%/yr) means a wide, bumpy range of outcomes, size positions accordingly.
- Downside scenario: the model's pessimistic (P10) 3-year path falls to ₹129.
MARKSANS volatility & expected range, how bumpy is the ride?
Over the last 2.0 years MARKSANS compounded at 23%/year with annualized volatility of 47%. That volatility implies a 1-year 80% range of ₹158–₹537, the honest backbone behind any single price target.
MARKSANS price forecast, the full 60-month probability fan
MARKSANS price probability fan
Each band shows where 10,000 simulated paths land. The wider the fan, the more uncertainty.
Probability of key outcomes
What are the odds MARKSANS hits common targets within the simulated horizon?
Full multi-horizon detail on the MARKSANS price target & forecast page.
MARKSANS Piotroski F-Score: 4/9, how financially strong is it?
The Piotroski F-Score grades financial strength on nine profitability, leverage and efficiency checks. MARKSANS scores 4/9,mixed financial health.
MARKSANS MTF margin & leverage, Upstox, Zerodha, Groww, Dhan
Margin Trading Facility lets you buy MARKSANS with part of the capital. Lower margin % = higher leverage. Rates compared across brokers (no competitor publishes this):
| Broker | Margin required | Approx. leverage |
|---|---|---|
| UpstoxCHEAPEST | 35.9% | 2.8× |
| ZerodhaCHEAPEST | 35.9% | 2.8× |
| DhanCHEAPEST | 35.9% | 2.8× |
Compare every broker on the MARKSANS MTF page.
MARKSANS vs peers,sector comparison
About Marksans Pharma: sector, index & market-cap context
Marksans Pharma (MARKSANS) is a small-cap NSE-listed company, and a constituent of the Nifty 200 index group, with a market capitalisation of ₹11,581 Cr. See more Nifty 200 stocks.
How the MARKSANS Snapshot Score & forecast are built
The Downstox Snapshot Score is a transparent, rules-based read of Marksans Pharma's public fundamentals plus a statistical forecast, not an analyst opinion. It rewards low-to-fair valuation, high ROE/ROCE, a strong Piotroski F-Score, a dividend, low volatility and a favourable probability of upside; it penalises rich valuations, weak capital efficiency, a low F-Score and high volatility. The price target is a 10,000-path Monte-Carlo simulation on real historical volatility, a distribution, not a single guess. The bull and bear cases are generated from the same data, so you always see both sides.
This is information, not investment advice. Do your own due diligence and consult a SEBI-registered adviser before investing.
MARKSANS analysis, FAQs
Is Marksans Pharma (MARKSANS) a good buy?
On the numbers, Marksans Pharma (MARKSANS) mixed signals, a Downstox Snapshot Score of 54/100, weighing premium at 27.7× earnings, ROE of 15.2%, a 60% model probability of trading higher in a year. This is a data snapshot for research, not investment advice.
Is MARKSANS overvalued or undervalued?
MARKSANS trades at 27.7× earnings versus a peer median of 15.9×, so it screens richer than its sector peers.
What is the MARKSANS share price target for 2031?
MARKSANS's probability-weighted 2031 median target is ₹472, with an 80% range of ₹122–₹1,841 (10,000-path Monte-Carlo).
What is the probability MARKSANS doubles in 5 years?
The modelled probability of MARKSANS reaching ₹519 (2×) within 5 years is 47%.
What is the bull case for MARKSANS?
A healthy 15.2% return on equity. Strong ROCE (18.8%) shows the core business earns well above its cost of capital. A 10,000-path probability model puts a 60% chance the price is higher in a year, with a median target of ₹293 (+13%).
What are the risks in MARKSANS?
At 27.7× earnings the stock carries a premium to the market, strong growth is already in the price, so any miss tends to be punished. High historical volatility (47%/yr) means a wide, bumpy range of outcomes, size positions accordingly.